Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes

Current Diabetes Reports

Volumn 9, Issue 1, 2009, Pages 18-25

  Averill, Michelle M ^b   Bornfeldt, Karin E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSE REDUCTASE INHIBITOR; DIACYLGLYCEROL; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN KINASE C; TOLL LIKE RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; MACROPHAGE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; VIRUS MENINGITIS;

ADIPOSE TISSUE; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; INFLAMMATION; LIPIDS; MACROPHAGES; MONOCYTES;

EID: 59749087035     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0005-x     Document Type: Review

References (50)

1. Ruderman NB, Haudenschild C: Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984, 26:373-412.
2. Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE: Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 2007, 100:769-781.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
4. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group [no authors listed]. N Engl J Med 2005, 353: 2643-2653.
5. McGarry JD: BantDng lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
6. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560-2572.
7. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545-2559.
8. Johansson F, Kramer F, Barnhart S, et al.: Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci U S A 2008, 105:2082-2087.
9. Rosenfeld ME, Averill MM, Bennett BJ, Schwartz SM: Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets 2008, 9:210-216.
10. Virmani R, Burke AP, Farb A, Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47(8 Suppl):C13-C18.
11. Gerrity RG, Natarajan R, Nadler JL, Kimsey T: Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001, 50:1654-1665.
12. Renard CB, Kramer F, Johansson F, et al.: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004, 114:659-668.
13. Aronson D: Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008, 45:1-16.
14. Vikramadithyan RK, Hu Y, Noh HL, et al.: Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005, 115:2434-2443.
15. Nakamura Y, Horii Y, Nishino T, et al.: Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993, 143:1649-1656.
16. Kalousova M, Skrha J, Zima T: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002, 51:597-604.
17. Shanmugam N, Figarola JL, Li Y, et al.: Proinflammatory effects of advanced lipoxidation end products in monocytes. Diabetes 2008, 57:879-888.
18. Soro-Paavonen A, Watson AM, Li J, et al.: RAGE deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469.
19. Harja E, Bu DX, Hudson BI, et al.: Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008, 118:183-194.
20. Bucciarelli LG, Wendt T, Qu W, et al.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106: 2827-2835.
21. Das Evcimen N, King GL: The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007, 55:498-510.
22. Dasu MR, Devaraj S, Ling Z, et al.: High glucose induces toll-like receptor expression in human monocytes: Mechanism of activation. Diabetes 2008, 57:3090-3098.
23. Newsholme P, Haber EP, Hirabara SM, et al.: Diabetes associated cell stress and dysfunction: Role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007, 583:9-24.
24. Pennathur S, Wagner JD, Leeuwenburgh C, et al.: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001, 107:853-860.
25. Averill MM, Bennett BJ, Rattazzi M, et al.: Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice. Atherosclerosis 2008 Jul 1 (Epub ahead of print).
26. Nakagami H, Kaneda Y, Ogihara T, Morishita R: Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diab Rev 2005, 1:59-63.
27. Piga R, Naito Y, Kokura S, et al.: Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007, 193:328-334.
28. Watada H, Azuma K, Kawamori R: Glucose fluctuation on the progression of diabetic macroangiopathy: New findings from monocyte adhesion to endothelial cells. Diabetes Res Clin Pract 2007, 77:S58-S61.
29. Devaraj S, Glaser N, Griffen S, et al.: Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006, 55:774-779.
30. Devaraj S, Dasu MR, Rockwood J, et al.: Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: Further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008, 93:578-583.
31. Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008, 371:1800-1809.
32. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
33. Swirski FK, Libby P, Aikawa E, et al.: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007, 117:195-205.
34. Tacke F, Alvarez D, Kaplan TJ, et al.: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007, 117:185-194.
35. Patiño R, Ibarra J, Rodriguez A, et al.: Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol 2000, 85:1288-1291.
36. Zaliunas R, Slapikas R, Babarskiene R, et al.: The prevalence of the metabolic syndrome components and their combinations in men and women with acute ischemic syndromes. Medicina (Kaunas) 2008, 44:521-528.
37. Ohman MK, Shen Y, Obimba CI, et al.: Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:798-805.
38. Beltowski J, Jamroz-Wisniewska A, Widomska S: Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008, 8:7-46.
39. Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
40. Li CJ, Sun HW, Zhu FL, et al.: Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. J Endocrinol 2007, 193:137-145.
41. Tsubakio-Yamamoto K, Matsuura F, Koseki M, et al.: Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008, 375:390-394.
42. Tian L, Luo N, Klein RL, et al.: Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2008 Apr 20 (Epub ahead of print).
43. Qiao L, Zou C, van der Westhuyzen DR, Shao J: Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 2008, 57:1824-1833.
44. Sheng T, Yang K: Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008, 35:321-326.
45. Dubey L, Hesong Z: Role of leptin in atherogenesis. Exp Clin Cardol 2006, 11:269-275.
46. Chiba T, Shinozaki S, Nakazawa T, et al.: Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008, 196:68-75.
47. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
48. Suganami T, Tanimoto-Koyama K, Nishida J, et al.: Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007, 27:84-91.
49. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al.: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
50. Duan SZ, Usher MG, Mortensen RM: Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102: 283-294.